JAL Therapeutics is currently seeking $3M - $5M in seed funding to complete preclinical research (safety, PK, PD, toxicology & CMC) for its lead drug candidate JAL-001 to treat Alzheimer’s disease (AD). This will set the stage for an IND application and first human clinical trials. The company has developed a patented, small molecule drug platform of highly selective butyrylcholinesterase (BChE) inhibitors. JAL-001 demonstrates a potent 68,000-fold selectivity over acetylcholinesterase (AChE) and is designed to restore the neurotransmitter acetylcholine to normal levels without side effects.
